. Author manuscript; available in PMC: 2008 Jan 15.

Published in final edited form as: Bioorg Med Chem. 2006 Nov 1;15(2):678–685. doi: 10.1016/j.bmc.2006.10.061

Table 2.

Pharmacological evaluation of MLA (1a) and MLA analogs 1b–f as nicotinic antagonists. Results were expressed as AD₅₀ (mg/kg) ± Confidence Limits (CL) or % effect at the highest dose tested.^a

compd	Seizures (AD₅₀ mg/kg)	Tail-Flick (AD₅₀ mg/kg)	Hot-Plate (AD₅₀ mg/kg)
1a	2 (0.5–4)	12 (2–59)	15% @ 20
1b	40% @ 50	10% @ 30	0% @ 30
1c	10 (9–11)	1.8 (0.4–9)	13% @ 20
1d	0% @ 50	7.0 (3–15)	25% @ 20
1e	0% @ 50	18.3 (10–31)	7% @ 20
1f	33 (10–113)	7.0 (2.5–18)	0% @ 20

Dose response curves were determined using a minimum of 4 different doses of test compound and at least eight mice were used per dose group.